Vertex Pharmaceuticals has successfully completed its acquisition of Crinetics Pharmaceuticals for about $10 billion in equity value, which amounts to approximately $8.8 billion after accounting for estimated cash acquired. This strategic move expands Vertex’s focus into the realm of rare endocrine diseases and enhances its portfolio with both commercial and clinical-stage assets that promise significant revenue opportunities.
The deal was finalized on September 1, 2026, after receiving the necessary regulatory clearances and shareholder approval from Crinetics. Vertex had initially announced the definitive agreement in July, setting the stage for this transformative acquisition.
New Assets and Pipeline Growth
With this acquisition, Vertex adds PALSONIFY (paltusotine) and atumelnant to its portfolio, along with a variety of other promising pipeline programs.
PALSONIFY is an oral therapy taken once daily for the treatment of acromegaly. It has already been launched in the United States, received approval in the European Union, and is currently under review in additional global markets.
Atumelnant, another once-daily oral medication, functions as an adrenocorticotropic hormone receptor antagonist. This drug is in Phase 3 clinical trials for congenital adrenal hyperplasia and in Phase 2 trials for Cushing’s syndrome.
Vertex estimates that PALSONIFY and atumelnant could generate over $5 billion in combined annual revenue at their peak, which underscores the revenue potential of this acquisition.
Accelerating Growth and New Strategic Focus
Vertex anticipates that the Crinetics acquisition will not only accelerate revenue growth but also strengthen its long-term earnings outlook. The company expects this acquisition to positively impact its non-GAAP operating income by 2029.
This transaction also positions rare endocrine diseases as a critical growth area for Vertex, complementing its existing interests in cystic fibrosis, hematology, acute pain, and renal disease.
Leadership Changes to Support Integration
In conjunction with the acquisition, Vertex has announced several significant changes to its executive leadership team.
Charles Wagner, who currently serves as Executive Vice President and Chief Operating and Financial Officer, will expand his role as Chief Operating Officer to oversee the integration of Crinetics.
In a planned leadership transition, Jonathan Poole, currently the Senior Vice President of Finance, will assume the role of Executive Vice President and Chief Financial Officer starting January 1, 2027. Wagner will continue as Executive Vice President and Chief Operating Officer.
Poole has been integral to Vertex’s global finance organization since March 2020, guiding the company through substantial R&D expansion and multiple acquisitions. Before joining Vertex, he held CFO positions at Evelo Biosciences and Genocea Biosciences, in addition to senior finance roles at Shire.
New Leadership for Product Planning
Vertex has appointed Jasper van Grunsven as Executive Vice President and Chief Pain and New Product Planning Officer, effective September 8. Van Grunsven will oversee Vertex’s pain franchise, including the management of JOURNAVX (suzetrigine) for moderate-to-severe acute pain and global new product planning.
He previously served as Senior Vice President at Amgen, focusing on their Rare Disease portfolio and global analytics. His extensive experience also includes positions at AbbVie, Abbott Laboratories, and Nycomed.
A Vision for the Future
“This is an exciting time for Vertex as we embark on our next phase of growth and diversification, driven by the rapid advancements in our R&D pipeline and commercial offerings,” said Reshma Kewalramani, M.D., Chief Executive Officer and President of Vertex Pharmaceuticals. “With the completion of the Crinetics acquisition, I am thrilled to welcome the talented Crinetics team to Vertex. Together, we will continue our efforts to launch PALSONIFY globally and accelerate the atumelnant program. I also want to congratulate Charlie and Jonathan on their new roles and warmly welcome Jasper to our team as we push forward in our mission to provide transformative medicines to patients worldwide.”
Key Takeaways
- Vertex Pharmaceuticals has acquired Crinetics Pharmaceuticals for approximately $10 billion, enhancing its portfolio in rare endocrine diseases.
- The acquisition includes PALSONIFY and atumelnant, both of which have significant revenue potential.
-
Leadership changes at Vertex aim to facilitate the integration of Crinetics and further support the company’s growth strategy.
In conclusion, Vertex Pharmaceuticals’ acquisition of Crinetics marks a pivotal step in its strategic expansion into rare endocrine diseases. With new products on the horizon and a strengthened leadership team, Vertex aims to enhance its market presence and deliver innovative therapies to patients globally.
Read more → pulse2.com